AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 141 min read$CGEM

Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3

Cullinan Therapeutics reported that its drug zipalertinib, combined with chemotherapy, showed a median progression-free survival of 14.5 months compared to 8.5 months with chemotherapy alone in the Phase 3 REZILIENT3 trial. The study included 279 patients with EGFR ex20ins NSCLC. The combination also achieved a higher objective response rate (65.0% vs. 40.3%) and longer median duration of response (14.2 vs. 9.9 months). Safety data showed higher Grade ≥3 adverse events with the combination, prim

Original reporting
tradingview.com
Published Sep 14, 2026, 11:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3 — source image
Source · tradingview.com
Decision brief

The 30-second read

$CGEMBullishHigh
01

Why it matters

The interim Phase 3 data represent the first public disclosure of efficacy outcomes, a material catalyst for the stock.

02

Market read

First‑report of pivotal trial data; likely triggers immediate price movement and re‑valuation of CGEM.

03

What to watch

The interim overall survival HR of 0.72 is not yet mature; market may overprice based on PFS alone.

Relevance 8/10Novelty 9/10Timing: today

Background

Cullinan Therapeutics (CGEM) is a US‑listed biotech focused on EGFR exon 20 insertion NSCLC therapies.

Company-level read

Ticker impact

$CGEMBullishHigh confidence
Context

Cullinan Therapeutics reported interim Phase 3 REZILIENT3 data showing median PFS 14.5 months vs 8.5 months, a significant efficacy improvement.

Expected impact

Expect short‑term upside as investors price in the efficacy data; potential 15‑25% rally.

Evidence & confidence

Phase 3 data with HR 0.50 and statistically significant P‑value is material for a biotech; market typically reacts strongly to such breakthroughs.

Market effects

Sector

Strengthens the EGFR‑targeted NSCLC segment and may benefit peer companies developing similar therapies.

Regional

Positive for US biotech sector; limited immediate regional effect.

Global

Adds to global oncology pipeline confidence, could influence investor sentiment in biotech indexes.

Counterpoint

What could challenge this read

Safety signals with higher Grade ≥3 adverse events could temper enthusiasm; long‑term overall survival benefit remains uncertain.

Key entities

  • Company
    Cullinan Therapeutics

    Biotech developer of zipalertinib.

  • Drug
    zipalertinib

    Investigational EGFR ex20ins inhibitor.

Read at source← All news

Related articles

SEP 14
$CGEMMedAI 8/10

Cullinan Therapeutics stock falls despite positive trial data

Cullinan Therapeutics (CGEM) shares fell 6.3% despite positive Phase 3 trial results for zipalertinib in lung cancer treatment. The REZILIENT3 trial met its primary endpoint, showing a 6.0-month improvement in median progression-free survival compared to chemotherapy alone. The company plans to discuss the results with health authorities. According to Cullinan, the trial enrolled 279 patients with advanced NSCLC.

investing.com2 min
SEP 14
MedAI 8/10

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics reported Phase 3 REZILIENT3 trial results, showing zipalertinib plus chemotherapy improved progression-free survival in EGFR exon 20 insertion mutation NSCLC patients. Median PFS increased by 6.0 months (HR=0.50). The companies view zipalertinib as a key growth driver, though earnings forecasts remain unchanged.

marketscreener.com6 min
SEP 13
$CGEMMedAI 8/10

Zipalertinib plus chemo shows survival benefit in lung cancer trial

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib plus chemotherapy in lung cancer. The combination improved progression-free survival by 6.0 months (14.5 vs. 8.5 months) with a hazard ratio of 0.50. The trial enrolled 279 patients, with objective response rates of 65.0% for the combination vs. 40.3% for chemotherapy alone. Zipalertinib is not yet approved.

investing.com2 min
SEP 13
$CGEMHighAI 8/10

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced positive Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC. The combination showed a 6.0-month median PFS improvement (HR=0.50, P=0.00015) and higher response rates. Data were presented at WCLC 2026. The companies plan to discuss results with health authorities.

finance.yahoo.com3 min